Desmopressin acetate nasal solution 0.01% (nasal spray) is available as a 5mL bottle containing an aqueous solution with the spray pump delivering 50 sprays of 10 mcg (0.1 mL) (NDC 47335-788-91). Store at Controlled Room Temperature 20 to 25ºC (68 to 77ºF); excursion permitted to 15°C to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. STORE BOTTLE IN UPRIGHT POSITION.
www.fda.gov/medwatchDesmopressin acetate nasal solution 0.01% (nasal spray) is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older.
Limitations of Use:
Desmopressin acetate nasal solution 0.01% (nasal spray) is not indicated for:
• Treatment of nephrogenic diabetes insipidus,
• Treatment of primary nocturnal enuresis [see Warnings and Precautions (5.1)],
• Use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see Warnings and Precautions (5.2)].
• Use in patients with an impaired level of consciousness,
• Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see Dosage Forms and Strengths (3)].
Administer desmopressin acetate nasal solution 0.01% (nasal spray) by intranasal use only. Instruct patients about appropriate fluid restriction during desmopressin acetate nasal solution 0.01% (nasal spray) treatment [see Warnings and Precautions (5.1)].
Must prime the spray pump prior to the first use. Instruct patients to:
• Prime pump by pressing down on pump four times (if the spray pump is not used for one week, re-prime the pump by pressing down on the pump once).
• Discard desmopressin acetate nasal solution 0.01% (nasal spray) after 50 sprays since the amount delivered thereafter may be substantially less than the recommended dosage.
The use of desmopressin acetate nasal solution 0.01% (nasal spray) is not indicated for patients who require less than 10 mcg doses or doses that are not multiples of 10 mcg because the spray pump can only deliver doses of 10 mcg [see Indications and Usage (1)]. If other doses are required, use another desmopressin acetate product.
Individualize the dosage of desmopressin acetate nasal solution 0.01% (nasal spray) for each patient with particular attention in pediatric and elderly patients and adjust according to the diurnal pattern of response to limit nocturia and to ensure fluid intake with respect to urine output is not excessive [see Warnings and Precautions (5.1)]. Monitor continued response to desmopressin acetate nasal solution 0.01% (nasal spray) by urine volume and osmolality to ensure adequate diuresis to limit the risk of hyponatremia, and include measurements of serum sodium and plasma osmolality as needed.
Adults
The recommended dosage in adults is 10 mcg once daily into one nostril up to 40 mcg once daily (or 40 mcg divided into two or three daily doses). If administered more than once a day, adjust for an adequate diurnal rhythm of urine output.
Pediatric Patients
• For pediatric patients requiring doses less than 10 mcg, desmopressin acetate nasal solution 0.01% (nasal spray) is not indicated.
• For pediatric patients 4 years of age and older, the recommended starting dosage of desmopressin acetate nasal solution 0.01% (nasal spray) is 10 mcg once daily into one nostril. The dose can be titrated up to 30 mcg once daily (or 30 mcg divided into two daily doses, typically with 20 mcg given in the morning and 10 mcg given at nighttime). If administered more than once a day, adjust for an adequate diurnal rhythm of urine output.
Because administration of desmopressin acetate can been associated with decreased responsiveness with prolonged use, consider increasing the dosage of desmopressin acetate nasal solution 0.01% (nasal spray) if patients demonstrate decreased response over a long period of time.
When switching from the desmopressin acetate injection to desmopressin acetate nasal solution 0.01% (nasal spray), administer 10 times the amount of desmopressin acetate, rounding down to the nearest 10 mcg.
When switching from the desmopressin acetate tablets to desmopressin acetate nasal solution 0.01% (nasal spray) individual dose titration is required because intranasal desmopressin is approximately 10 to 40 fold more potent than oral (tablet) desmopressin.
Desmopressin acetate nasal solution 0.01% (nasal spray) pump delivers 10 mcg (0.1 mL) of desmopressin acetate per spray.
Desmopressin acetate nasal solution 0.01% (nasal spray) is available as a 5 mL bottle with spray pump delivering 50 sprays.
Desmopressin acetate nasal solution 0.01% (nasal spray) is contraindicated in patients with:
• Known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate nasal solution 0.01% (nasal spray). Severe allergic reactions and anaphylaxis have been reported [see Adverse Reactions (6)].
• Renal impairment defined as estimated creatinine clearance (CLcr) by Cockcroft-Gault equation less than 50 mL/min
[see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
• Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1)].
Excessive fluid intake when urine output is limited by the antidiuretic effect of desmopressin may lead to water intoxication with hyponatremia. Cases of hyponatremia have been reported from postmarketing experience in patients treated with desmopressin acetate. Unless properly diagnosed and treated, hyponatremia can be fatal.
All patients receiving desmopressin acetate nasal solution 0.01% (nasal spray) should be observed for the following signs or symptoms associated with hyponatremia: headache, nausea/vomiting, decreased serum sodium, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss appetite, irritability, muscle weakness, muscle spasms or cramps and abnormal mental status such as hallucinations, decreased consciousness, and confusion. Severe symptoms due to an extreme decrease in serum sodium and plasma osmolality may include one or a combination of the following: seizure, coma, and/or respiratory arrest.
In order to decrease the risk of water intoxication with hyponatremia, fluid restriction is recommended. Careful fluid intake restriction is particularly important in pediatric and geriatric patients because these patients are at greater risk of developing hyponatremia [see Use in Specific Populations (8.4, 8.5)]. More frequent monitoring of serum sodium levels is recommended in the following patients: those with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, heart failure, renal disorders, habitual or psychogenic polydipsia or those taking concomitant drugs that may cause hyponatremia [see Drug Interactions (7.1)].
Desmopressin acetate nasal solution 0.01% (nasal spray) is not an indicated formulation for the treatment of primary nocturnal enuresis due to a higher risk of hyponatremia and hyponatremic convulsions with the use of the nasal spray formulation compared to desmopressin tablets seen in postmarketing reports [see Indications and Usage (1)].
Chronic administration of desmopressin acetate nasal solution 0.01% (nasal spray) may result in changes to nasal mucosa. Nasal mucosa abnormalities (such as scarring and edema) due to chronic administration, or due to other causes (nasal blockage, nasal mucosal atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) may cause erratic, unreliable absorption. Avoid use of desmopressin acetate nasal solution 0.01% (nasal spray) in such patients [see Indications and Usage (1)] and consider use of other formulations of desmopressin acetate given by other routes of administration.
The following serious reactions are described below and elsewhere in the labeling:
• Hyponatremia [see Warnings and Precautions (5.1)].
• Altered Absorption in Patients with Changes in Nasal Mucosa [see Warnings and Precautions (5.2)].
The following adverse reactions have been identified during post-approval use of desmopressin acetate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
Increase in blood pressure, headache, nasal congestion, rhinitis, nosebleed, sore throat, cough, upper respiratory infections, nausea, flushing, and abdominal cramps.
Water intoxication with hyponatremia
Hyponatremic convulsions associated with concomitant use of the following medications: oxybutinin and imipramine [see Drug Interactions (7.1)].
Severe allergic reactions and anaphylaxis [see Contraindications (4)]
The concomitant administration of desmopressin acetate nasal solution 0.01% (nasal spray) with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine, oxybutynin and carbamazepine) requires more frequent serum sodium monitoring [see Warnings and Precautions (5.1) and Adverse Reactions (6)].
Desmopressin acetate can elevate blood pressure. Use of large doses of desmopressin acetate nasal solution 0.01% (nasal spray) with other vasocontrictors may require a reduction of the desmopressin acetate nasal solution 0.01% (nasal spray) dosage [see Adverse Reactions (6)].
Risk summary
Prolonged experience with desmopressin in pregnant women over several decades, based on the available published data and case reports, did not identify a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In addition, in vitro studies with human placenta demonstrate poor placental transfer of desmopressin. No adverse developmental outcomes were observed in animal reproduction studies with administration of desmopressin during organogenesis to pregnant rats and rabbits at doses approximately <1 and 38 times, respectively, the maximum recommended human dose based on body surface area (mg/m2) (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data
Animal Data
Desmopressin acetate at up to 50 ng/kg/day was given by subcutaneous injection to pregnant rats, from gestation day 1 to 20 during the period of early embryonic development and organogenesis without teratogenic effects. Desmopressin acetate at up to 10 mcg/kg/day was given to pregnant rabbits by subcutaneous injection from gestation day 6 to 18 during fetal organogenesis without teratogenic effects. These doses of desmopressin acetate represent approximately <1 times (rat) and 38 times (rabbit) the maximum recommended human dose based on body surface area (mg/m2).
Risk Summary
Breastfeeding is not expected to result in clinically relevant exposure of the infant to desmopressin following maternal intranasal administration. Desmopressin is poorly transferred into human breastmilk at negligible amounts (see Data). There is no information on the effects of desmopressin on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for desmopressin acetate nasal solution 0.01% (nasal spray) and any potential adverse effects on the breastfed infant from desmopressin acetate nasal solution 0.01% (nasal spray) or from the underlying maternal condition.
Data
A trial was conducted in six healthy lactating women, at greater than 4 months postpartum, to evaluate intranasal administration of 300 mcg single dose of another desmopressin product (7.5 times the recommended adult dose of desmopressin acetate nasal solution 0.01% (nasal spray). Samples of maternal plasma and breastmilk were obtained at 0, 30, 60, 120, 240, 360 and 480 min after the drug administration. At 8 hours after dose intake, the levels in the milk ranged between 4.16 and 101 pg/ml, and the plasma levels ranged between 40 and 242 pg/ml. The total amount of desmopressin present in the milk over the 8 hours ranged between 491 pg and 16 ng, which corresponds to 0.0001 - 0.005% of the administered dose to the breastfeeding mother.
Desmopressin acetate nasal solution 0.01% (nasal spray) is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in pediatric patients 4 years of age and older. Desmopressin acetate nasal solution 0.01% (nasal spray) is not indicated in pediatric patients less than 4 years of age.
Use of desmopressin acetate nasal solution 0.01% (nasal spray) in pediatric patients 4 years of age and older is supported by evidence from adults and pediatric patients with central diabetes insipidus. Use in pediatric patients requires careful fluid intake restriction to prevent possible water intoxication with hyponatremia [see Warnings and Precautions (5.1)].
Clinical studies of desmopressin acetate nasal solution 0.01% (nasal spray) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at a low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.
Because elderly patients are more likely to have renal impairment, care should be taken in dose selection, and monitoring renal function is recommended [see Contraindications (4), Use in Specific Populations (8.6)].
Use of desmopressin acetate nasal solution 0.01% (nasal spray) in geriatric patients requires careful fluid intake restriction to prevent possible water intoxication with hyponatremia [see Warnings and Precautions (5.1)].
Desmopressin acetate is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with renal impairment than patients with normal renal function. Desmopressin acetate nasal solution 0.01% (nasal spray) is contraindicated in patients with estimated CLcr by Cockcroft-Gault equation less than 50 mL/min [see Clinical Pharmacology (12.1, 12.3), Contraindications (4)].
Signs of desmopressin acetate overdosage may include confusion, drowsiness, continuing headache, problems with passing urine, and rapid weight gain due to fluid retention [see Warnings and Precautions (5.1)]. In case of overdosage, reduce the dosage, decrease the frequency of administration, or discontinue desmopressin acetate nasal solution 0.01% (nasal spray). There is no known specific antidote for desmopressin acetate.
Desmopressin acetate, USP is a vasopressin analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:
Molecular weight: 1183.34
Molecular formula: C46H64N14O12S2•C2H4O2•3H2O
1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.
Desmopressin acetate nasal solution 0.01% (nasal spray) is an aqueous solution for intranasal use.
Each mL contains:
Desmopressin acetate, USP 0.1 mg
Sodium chloride 7.5 mg
Citric acid monohydrate 1.7 mg
Disodium phosphate dihydrate 3 mg
Benzalkonium chloride solution (50%) 0.2 mg
The antidiuretic effects of desmopressin are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. Desmopressin is a replacement hormone for antidiuretic hormone in the treatment of central diabetes insipidus. The change in structure of arginine vasopressin to desmopressin acetate resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses were usually below threshold levels for effects on vascular or visceral smooth muscle.
The use of desmopressin acetate nasal solution 0.01% (nasal spray) in patients with central diabetes insipidus reduces urinary output, increases urine osmolality, and decreases plasma osmolality.
Absorption: Desmopressin acetate is absorbed through the nasal mucosa.
Elimination: Desmopressin acetate exhibits a biphasic elimination profile, with half-lives of 7.8 and 75.5 minutes for the initial and terminal phases, respectively.
Specific Populations
Renal Impairment: Desmopressin acetate is mainly excreted in the urine. A pharmacokinetic study was conducted in subjects with normal renal function and patients with mild, moderate, and severe renal impairment (n=24, 6 subjects each group) with a single 2 mcg dose of desmopressin acetate injection (this results in approximately 20 times the exposure of 10 mcg of desmopressin acetate nasal solution 0.01% (nasal spray). The terminal half-life was 2.8 hours in subjects with normal renal function, 4.0 hours in mild renal impairment, 6.6 hours in moderate renal impairment and 8.7 hours in severe renal impairment. In patients with mild, moderate and severe renal impairment, mean desmopressin exposure was 1.5 fold, 2.4 fold and 3.6 fold higher, respectively compared to that of subjects with normal renal function [see Contraindications (4), Use in Specific Populations (8.6)].
Studies with desmopressin acetate have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.
Desmopressin acetate nasal solution 0.01% (nasal spray) is available as a 5mL bottle containing an aqueous solution with the spray pump delivering 50 sprays of 10 mcg (0.1 mL) (NDC 47335-788-91).
Store at Controlled Room Temperature 20 to 25ºC (68 to 77ºF); excursion permitted to 15°C to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. STORE BOTTLE IN UPRIGHT POSITION.
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use)
Administration
• Inform caregivers for pediatric patients that administration should be supervised to ensure the patient receives the prescribed dose.
• Inform patients that the pump must be primed prior to first use and again if not used for greater than one week. Inform patients that the desmopressin acetate nasal solution 0.01% (nasal spray) bottle delivers 50 sprays of 10 mcg each following the initial 4 priming pumps.
• Inform patients to discard any solution remaining after 50 sprays since the amount delivered thereafter may be substantially less than 10 mcg of drug.
Monitoring
• Educate patients about the signs and symptoms of hyponatremia and advise them to contact a healthcare provider if such symptoms occur.
• Discuss downward adjustment of fluid intake and monitoring of urine output with patients.
Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Manufactured by:
Sun Pharmaceutical Industries Ltd.
Halol-Baroda Highway,
Halol-389 350, Gujarat, India.
ISS. 01/2019
PJPI0438C
| Patient Information Desmopressin Acetate (DEZ-mo-press-in AS-e-tate) Nasal Solution, 0.01% (Nasal Spray) for Intranasal Use Only |
| What is desmopressin acetate nasal solution 0.01% (nasal spray)? Desmopressin acetate nasal solution 0.01% (nasal spray) is a prescription medicine called a vasopressin analog used as an antidiuretic replacement to manage central diabetes insipidus.
|
| Who should not use desmopressin acetate nasal solution 0.01% (nasal spray)? Do not use desmopressin acetate nasal solution 0.01% (nasal spray) if you:
|
| What should I tell my healthcare provider before using desmopressin acetate nasal solution 0.01% (nasal spray)? Before using desmopressin acetate nasal solution 0.01% (nasal spray), tell your healthcare provider about all your medical conditions including if you:
|
How should I use desmopressin acetate nasal solution 0.01% (nasal spray)?
|
| What are the possible side effects of desmopressin acetate nasal solution 0.01% (nasal spray)? Desmopressin acetate nasal solution 0.01% (nasal spray) may cause serious side effects including:
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
| General information about the safe and effective use of desmopressin acetate nasal solution 0.01% (nasal spray). Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use desmopressin acetate nasal solution 0.01% (nasal spray) for a condition for which it was not prescribed. Do not give desmopressin acetate nasal solution 0.01% (nasal spray) to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about desmopressin acetate nasal solution 0.01% (nasal spray) that is written for health professionals. For more information call 1-800-818-4555. |
| What are the ingredients in desmopressin acetate nasal solution 0.01% (nasal spray)? Active ingredient: desmopressin acetate, USP Inactive ingredients: benzalkonium chloride solution (50%), sodium chloride, citric acid monohydrate, disodium phosphate dihydrate |
This Patient Information has been approved by the Food and Drug Administration
Desmopressin Acetate Nasal Solution 0.01% (Nasal Spray)
10 mcg per 0.1 mL for Intranasal Use Only
Read these instructions before using desmopressin acetate nasal solution 0.01% (nasal spray), and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Children should be helped by an adult when using desmopressin acetate nasal solution 0.01% (nasal spray), to make sure the right amount of medicine is used.
The parts of your desmopressin acetate nasal solution 0.01% (nasal spray) pump
(see Figure A):
Priming your Desmopressin Acetate Nasal Solution 0.01% (Nasal Spray):
Your desmopressin acetate nasal solution 0.01% (nasal spray) pump must be primed before you use it for the first time.
• Remove the protective cap (see Figure B).
• Press down on the shoulders at the top of your desmopressin acetate nasal solution 0.01% (nasal spray) pump 4 times. Hold the spray tip away from your face and eyes (see Figure C).
• After your desmopressin acetate nasal solution 0.01% (nasal spray) pump is primed, it will spray 10 micrograms (1 dose) of medicine each time it is pressed.
Using your Desmopressin Acetate Nasal Solution 0.01% (Nasal Spray):
Step 1. Remove the protective cap.
Step 2. To make sure you get the right dose of hold bottle upright (see Figures D).
Step 3. Put the spray nozzle tip of your desmopressin acetate nasal solution 0.01% (nasal spray) into your nostril and press the spray pump 1 time for 1 dose (see Figure E). If 2 doses are prescribed, spray each nostril 1 time.
Step 4. Put the protective cap back on the spray nozzle tip when you finish using your desmopressin acetate nasal solution 0.01% (nasal spray).
Keeping track of your Nasal Sprays:
• Use the check-off chart to help you keep track of your desmopressin acetate nasal solution 0.01% (nasal spray) used (see Figure F).
Desmopressin Acetate Nasal Solution 0.01% (Nasal Spray)
50-Spray Check-off Chart
• Keep this chart with your desmopressin acetate nasal solution 0.01% (nasal spray) or put it someplace where you can easily get it.
• Check off number 1 on the chart with your first dose of desmopressin acetate nasal solution 0.01% (nasal spray). Check off the numbers after each use of your desmopressin acetate nasal solution 0.01% (nasal spray). If your healthcare provider prescribed a 2-spray dose, then 2 numbers should be checked off.
• Your desmopressin acetate nasal solution 0.01% (nasal spray) holds 50 sprays with the right amount of medicine in each spray.
• If any medicine is left in your desmopressin acetate nasal solution 0.01% (nasal spray) after 50 sprays, do not use it. You may not get the right amount of medicine.
• Throw away your desmopressin acetate nasal solution 0.01% (nasal spray) after 50 sprays.
• Do not count the priming sprays. Your desmopressin acetate nasal solution 0.01% (nasal spray) has been filled with extra medicine for your priming sprays.
• Do not try to remove any medicine from your desmopressin acetate nasal solution 0.01% (nasal spray) pump and place it in another bottle.
How should I store desmopressin acetate nasal solution 0.01% (nasal spray)?
• Store desmopressin acetate nasal solution 0.01% (nasal spray) at room temperature between 68ºF to 77ºF (20ºC to 25ºC).
• Store desmopressin acetate nasal solution 0.01% (nasal spray) standing upright.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Manufactured by:
Sun Pharmaceutical Industries Ltd.
Halol-Baroda Highway,
Halol-389 350, Gujarat, India.
Rev. 01/19
Desmopressin Acetate Nasal Solution 0.01% - Bottle Label
NDC 47335-788-91
Desmopressin Acetate Nasal Solution 0.01% (Nasal Spray)
10 mcg/0.1 mL per spray
50 doses in a 5 mL bottle
Rx only
Needs no refrigeration
Desmopressin Acetate Nasal Solution 0.01% - Carton
NDC 47335-788-91
Desmopressin Acetate Nasal Solution 0.01% (Nasal Spray)
10 mcg/0.1 mL per spray
(0.01 mg/Spray)
FOR INTRANASAL USE ONLY
Needs no refrigeration
50 doses in a 5 mL bottle
Rx only
SUN PHARMA
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 47335-788-91 | ML - Milliliter | 47335-788 | 7f81f9ea-0417-422b-b361-24a120761277 | 1 | 2014-05-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| DESMOPRESSIN ACETATE | ACTIVE INGREDIENT | XB13HYU18U | 2 | |
| DESMOPRESSIN | ACTIVE MOIETY | ENR1LLB0FP | 2 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 2 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 2 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | INACTIVE INGREDIENT | 94255I6E2T | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 47335-788 | 47335-788-91 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DESMOPRESSIN ACETATE | XB13HYU18U | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | 94255I6E2T | IACT |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INFILTRATION | 648 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | ELIXIR / ORAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / AURICULAR (OTIC) | 18 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INHALANT / RESPIRATORY (INHALATION) | 3 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 38 mg | ||
| SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | 94255I6E2T | CAPSULE, DELAYED RELEASE / ORAL | 18 mg | ||
| SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | 94255I6E2T | OINTMENT / TOPICAL | 4 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, FILM COATED / ORAL | 100 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRABURSAL | 9 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EXTENDED RELEASE / ORAL | 45 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | JELLY / NASAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOAP / TOPICAL | 0.5 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBCUTANEOUS | 1486 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAMUSCULAR | 1486 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / AURICULAR (OTIC) | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / AURICULAR (OTIC) | 3 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TROCHE / ORAL | 12 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAVENOUS | 90 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAVENOUS | 2068 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / OPHTHALMIC | 55 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUPPOSITORY / RECTAL | 140 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 226 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOAP / TOPICAL | 1.26 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / PERIDURAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVITREAL | 10 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PARENTERAL | 584 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / RETROBULBAR | 648 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, EMULSION / INTRAVENOUS | 0.62 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION, LIPOSOMAL / EPIDURAL | 11 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, DENTIFRICE / DENTAL | 0.03 mg/mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ENDOTRACHEAL | 46.76 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRA-ARTICULAR | 26 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY, METERED / NASAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYSTEM / TOPICAL | 3.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / AURICULAR (OTIC) | 18 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / NASAL | 2.8 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / NASAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRASYNOVIAL | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1800 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / ORAL | 148 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAVENOUS | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBARACHNOID | 0.9 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | DESMOPRESSIN ACETATE | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | 2013-12-23 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | 2013-12-23 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | 2013-12-23 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | 2013-12-23 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | 2013-12-23 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | 2013-12-23 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A078271-001 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | 0.01MG/SPRAY | SPRAY, METERED / NASAL | AB | RS | 2013-12-23 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A078271-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A078271-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A078271-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A078271-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A078271-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A078271-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A078271-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A078271-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A078271-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A078271-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A078271-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A078271-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A078271-001 | AB | 1 | ea99ee380514… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A078271-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A078271-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A078271-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A078271-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A078271-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A078271-001 | AB | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A078271-001 | AB | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A078271-001 | AB | 1 | cb3db0bc1861… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| cd75d9e2-93ec-4736-a87d-b708933d9e0a | b47d691e-28a9-4e10-92b8-310aecc2f953 | 2023-09-01 | Warnings, Adverse reactions | b47d691e-28a9-4e10-92b8-310aecc2f953 |
Adverse event summaries are temporarily unavailable. Other product information remains available.